Table 2.
Univariate Analysis of Predictors of Posttransplant HCC Recurrence in the Development Cohort by Cox Proportional Hazards Regression
| Predictora | Univariate HR (95% CI) | P Value |
|---|---|---|
| AFP at LT, ng/mL [Reference, ≤20] | ||
| 21–99 | 2.03 (1.19–3.49) | .01 |
| 100–999 | 3.26 (1.82–5.85) | <.001 |
| ≥1000 | 11.63 (5.61–24.09) | <.001 |
| Microvascular invasion | 7.82 (4.96–12.33) | <.001 |
| Largest viable tumor diameter (cm) + No. of tumors [Reference, 0]b | ||
| 1–4.9 | 1.99 (0.93–4.24) | .08 |
| 5–9.9 | 4.60 (2.21–9.56) | <.001 |
| ≥10 | 22.51 (9.57–52.94) | <.001 |
| Tumor differentiation [Reference, completely necrotic tumor] | ||
| Well | 1.78 (0.84–3.73) | .13 |
| Moderate | 3.02 (1.54–5.96) | .001 |
| Poor | 5.51 (2.62–11.58) | <.001 |
| HCC lesions, No. at diagnosis | ||
| 2 vs 1 | 1.06 (0.62–1.78) | .84 |
| 3 vs 1 | 1.84 (0.94–3.61) | .08 |
| Wait time from HCC diagnosis to LT | ||
| <6 Months | 1.44 (0.90–2.31) | .13 |
| >18 Months | 1.84 (0.99–3.41) | .06 |
Abbreviations: AFP, α-fetoprotein; HCC, hepatocellular carcinoma; HR, hazard ratio; LRT, loco-regional therapy; LT, liver transplantation; MELD, Model for End-Stage Liver Disease.
a
Age, sex, race/ethnicity, MELD score, cause of liver disease, number of lesions at HCC diagnosis, and LRT (vs no LRT) were not predictive of HCC recurrence on univariate analysis.
b
Largest viable tumor diameter (cm) + No. of viable tumors = 0 if no viable tumor is identified.